{"id":"W3133701599","doi":"10.1002/ajh.26147","title":"Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the <scp>MCRN</scp>‐003/<scp>MYX</scp>.1 single arm phase <scp>II</scp> trial","year":2021,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen's University; Ottawa Hospital; University of Ottawa; Western University; Saint John Regional Hospital; Hôtel-Dieu de Québec; Hotel Dieu Hospital; Princess Margaret Cancer Centre; Micropharma (Canada); University of Alberta; University of New Brunswick; Université de Montréal; Queen Elizabeth II Health Sciences Centre; Dalhousie University; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal","funders":"Amgen Canada; Amgen","keywords":"Carfilzomib; Lenalidomide; Medicine; Dexamethasone; Multiple myeloma; Regimen; Clinical endpoint; Internal medicine; Cyclophosphamide; Adverse effect; Gastroenterology; Phases of clinical research; Metastatic breast cancer; Thalidomide; Progression-free survival; Refractory (planetary science); Oncology; Neutropenia; Toxicity; Chemotherapy; Clinical trial; Cancer; Breast cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001234323,0.0006442278,0.001349565,0.0002464344,0.0002475397,0.0006859505,0.0003881812,0.0005690177,0.001591099],"category_scores_gemma":[0.0005210065,0.0002050151,0.0007837516,0.0003127804,0.0003737746,0.0003357223,0.0001817122,0.001687694,0.0002238257],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000784368,"about_ca_system_score_gemma":0.0007288094,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001858445,"about_ca_topic_score_gemma":0.007949933,"domain_scores_codex":[0.9997409,0.0001279999,0.00001300943,0.00003212064,0.00003359517,0.00005239343],"domain_scores_gemma":[0.9996477,0.00006505972,0.00006757544,0.00002091163,0.00001758443,0.0001810869],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7447882,0.008328636,0.00608092,0.001284543,0.002412347,0.0002357812,0.0002338593,0.002901851,0.02276281,0.0002921419,0.007188383,0.2034905],"study_design_scores_gemma":[0.7636078,0.1870796,0.03443069,0.0001755751,0.001816005,0.000404022,0.00009636109,0.00202767,0.003249729,0.0003438011,0.006730276,0.00003847064],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9849759,0.01082215,0.0002653061,0.00092696,0.0001640095,0.0004774619,0.00065123,0.000061867,0.001655131],"genre_scores_gemma":[0.9910606,0.004251206,0.0006426813,0.0006601486,0.0001788387,0.0003285149,0.00108455,0.00001585633,0.001777558],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001858445,"threshold_uncertainty_score":0.006527781,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04164704233889885,"score_gpt":0.3148523281370852,"score_spread":0.2732052857981864,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}